Insmed (INSM) closed at $114.41 on November 6, 2026, up 5.2% from the previous close, on volume of 3,121,338 shares (30-day average 3,493,318).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 27, 2026 | Call Spread | 15-Jan-27100 : 130 C | 20,166 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Thu, 5-Nov 5:31 PM ET)
Insmed’s Sinus Study Reaches Completion: What INSM Investors Should Watch
TipRanks (Wed, 4-Nov 11:30 AM ET)
Insmed to Present at November and December 2026 Investor Conferences
PRNewswire (Wed, 4-Nov 7:00 AM ET)
Insmed soars as BRINSUPRI hits $400.10 million in Q3 revenue and 2026 guidance rises
Market Chameleon (Thu, 29-Oct 7:05 AM ET)
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Thu, 29-Oct 7:01 AM ET)
Insmed Appoints Two New Directors to Its Board
PRNewswire (Tue, 20-Oct 7:00 AM ET)
PRNewswire (Mon, 19-Oct 7:00 AM ET)
PRNewswire (Thu, 15-Oct 7:00 AM ET)
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
PRNewswire (Wed, 14-Oct 7:01 AM ET)
Insmed Sets CFO Exit Date as It Reaffirms 2026 Revenue Guidance for BRINSUPRI and ARIKAYCE
Market Chameleon (Mon, 5-Oct 7:51 AM ET)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of November 6, 2026, INSM stock price climbed to $114.40 with 3,121,338 million shares trading.
INSM has a beta of 0.41, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.01 to the broad based SPY ETF.
INSM has a market cap of $25.10 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $524 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $25 million and missed earnings estimates by -$.09.
In the last 3 years, INSM traded as high as $212.75 and as low as $21.92.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VXF, VB, VO, VUG.
INSM has underperformed the market in the last year with a return of -38.4%, while the SPY ETF gained +10.8%. In the last 3 month period, INSM fell short of the market, returning -13.7%, while SPY returned -4.1%. However, in the most recent 2 weeks INSM has outperformed the stock market by returning +22.5%, while SPY returned -3.2%.
INSM support price is $105.82 and resistance is $111.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.
